Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes

Tatovic, D. ORCID: https://orcid.org/0000-0002-3879-2686, McAteer, M. A., Barry, J., Barrientos, A., Rodríguez Terradillos, K., Perera, I., Kochba, E., Levin, Y., Dul, M., Coulman, S. A. ORCID: https://orcid.org/0000-0002-1277-7584, Birchall, J. C. ORCID: https://orcid.org/0000-0001-8521-6924, von Ruhland, C., Howell, A., Stenson, R., Alhadj Ali, M., Luzio, S. D., Dunseath, G., Cheung, W. Y., Holland, G., May, K., Ingram, J. R. ORCID: https://orcid.org/0000-0002-5257-1142, Chowdhury, M. M. U., Wong, F. S. ORCID: https://orcid.org/0000-0002-2812-8845, Casas, R., Dayan, C. ORCID: https://orcid.org/0000-0002-6557-3462 and Ludvigsson, J. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) , ltac002. 10.1093/immadv/ltac002

[thumbnail of ltac002.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (14MB) | Preview

Abstract

Antigen-specific immunotherapy is immunomodulatory strategy for autoimmune diseases, such as Type 1 diabetes, in which patients are treated with autoantigens to promote immune tolerance, stop autoimmune beta-cell destruction and prevent permanent dependence on exogenous insulin. In this study, human proinsulin peptide C19-A3 (known for its positive safety profile) was conjugated to ultrasmall gold nanoparticles (GNP), an attractive drug delivery platform due to the potential anti-inflammatory properties of gold. We hypothesised that microneedle intradermal delivery of C19-A3 GNP may improve peptide pharmacokinetics and induce tolerogenic immunomodulation and proceeded to evaluate its safety and feasibility in a first-in-human trial. Allowing for the limitation of the small number of participants, intradermal administration of C19-A3 GNP appears safe and well-tolerated in participants with Type 1 diabetes. The associated prolonged skin retention of C19-A3 GNP after intradermal administration offers a number of possibilities to enhance its tolerogenic potential, which should be explored in future studies.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Pharmacy
Additional Information: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN: 2732-4303
Date of First Compliant Deposit: 15 February 2022
Date of Acceptance: 9 December 2021
Last Modified: 07 May 2023 18:46
URI: https://orca.cardiff.ac.uk/id/eprint/147484

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics